Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | FNTA | P49354 | 3/20 | 0.39 |
| ▸ | FNTB | P49356 | 3/20 | 0.39 |
| ▸ | CDC25A | P30304 | 1/20 | 0.38 |
| ▸ | CDC25B | P30305 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.38 |
| ▸ | MAPT | P10636 | 7/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14927688 | 0.89 | NTRK1 (0.40) | ALDH1A1POLBKDM4EMAPTHPGD | |
| SCHEMBL322528 | 0.86 | DAPK3 (0.42) | ALDH1A1POLBHSD17B10KDM4EMAPT | |
| SCHEMBL321841 | 0.85 | MAPT (0.42) | ALDH1A1POLBCDC25ACDC25BHSD17B10 | |
| SCHEMBL5316570 | 0.81 | ALDH1A1 (0.47) | ALDH1A1HSD17B10KDM4EMAPTHPGD | |
| SCHEMBL2710132 | 0.81 | SERPINE1 (0.50) | ALDH1A1POLBMAPTHPGDKMT2A | |
| SCHEMBL15094046 | 0.80 | RAB9A (0.42) | ALDH1A1POLBHSD17B10KDM4EMAPT | |
| SCHEMBL28177727 | 0.80 | ALDH1A1 (0.45) | ALDH1A1POLBCDC25BKDM4EMAPT | |
| SCHEMBL27701909 | 0.79 | MAPT (0.37) | ALDH1A1FNTAFNTBCDC25ACDC25B | |
| SCHEMBL1572758 | 0.78 | FNTA (0.44) | ALDH1A1POLBFNTAFNTBCDC25A | |
| SCHEMBL321531 | 0.76 | FNTA (0.46) | ALDH1A1POLBFNTAFNTBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732078-B2 | Therapeutic use of imidazopyridine derivatives | SANOFI (FR) | 2017-08-15 | — | — | US | disclosed |
| US-9732078-B2 | Therapeutic use of imidazopyridine derivatives | SANOFI (FR) | 2017-08-15 | — | — | US | disclosed |
| US-9732078-B2 | Therapeutic use of imidazopyridine derivatives | SANOFI (FR) | 2017-08-15 | — | — | US | disclosed |
| US-9452164-B2 | Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof | SANOFI (FR) | 2016-09-27 | — | — | US | disclosed |
| US-9452164-B2 | Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof | SANOFI (FR) | 2016-09-27 | — | — | US | disclosed |
| EP-2800566-B1 | THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES | SANOFI SA (FR) | 2015-10-28 | — | — | EP | disclosed |
| EP-2590976-B1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2015-09-16 | — | — | EP | disclosed |
| US-20140343054-A1 | Therapeutic Use of Imidazopyridine Derivatives | SANOFI (FR) | 2014-11-20 | — | — | US | disclosed |
| US-20140343054-A1 | Therapeutic Use of Imidazopyridine Derivatives | SANOFI (FR) | 2014-11-20 | — | — | US | disclosed |
| CN-104144687-A | THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES | SANOFI SA | 2014-11-12 | — | — | CN | disclosed |
| US-8759344-B2 | Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-06-24 | — | — | US | disclosed |
| US-8633216-B2 | Imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same | SANOFI (FR) | 2014-01-21 | — | — | US | disclosed |
| EP-2590976-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-15 | — | — | EP | disclosed |
| US-20130116250-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-09 | — | — | US | disclosed |
| US-20130116250-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-09 | — | — | US | disclosed |
| CN-103080111-A | Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof | SANOFI SA | 2013-05-01 | — | — | CN | disclosed |
| WO-2012004732-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-01-12 | — | — | WO | disclosed |
| US-8008321-B2 | Imidazo[1,5-a]pyridin-3-yl)(3-methoxy-4-nitrophenyl)methanone; a and b fibroblast growth factor receptors (FGFR) antagonist; anticarcinogenic, antitumor: lung, breast, prostate, melanomas, gliomas; antiinflammatory, vascular smooth muscle cells: atherosclerosis, restenosis, stent and bypass complications | SANOFI-AVENTIS (FR) | 2011-08-30 | — | — | US | disclosed |
| US-20110136856-A1 | Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2011-06-09 | — | — | US | disclosed |
| US-20080108648-A1 | Novel imidazo[1,5-a] pyridine derivatives, method for preparing same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343054-A1 | Therapeutic Use of Imidazopyridine Derivatives | CCNY, UTS2R, WNK2 | ALDH1A1 2378/4885POLB 2875/4885FNTA 3756/4885 |
| US-20130116250-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CCNY, ENY2, PAH | ALDH1A1 2306/4885POLB 943/4885FNTA 3161/4885 |
| US-20080108648-A1 | Novel imidazo[1,5-a] pyridine derivatives, method for preparing same and pharmaceutical compositions containing same | CYP3A5, CYP4B1, CYP3A7 | ALDH1A1 238/4885POLB 4487/4885FNTA 1039/4885 |
| US-20110136856-A1 | Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same | P2RX6, IL5, ATIC | ALDH1A1 711/4885POLB 4706/4885FNTA 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.